A BIOLOGICAL PERSPECTIVE OF BREAST-CANCER - CONTRIBUTIONS OF THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT CLINICAL-TRIALS

[31] Fisher B, Costantino J, Redmond C, Et al., A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumors, N Engl J Med, 320, pp. 479-484, (1989)

[32] Fisher B, Redmond C, Wickerham L, Et al., Systemic therapy in patients with node‐negative breast cancer: A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials, Ann Intern Med, 111, pp. 703-712, (1989)

[33] Fisher B, Gunduz N, Coyle J, Et al., Presence of a growth‐stimulating factor in serum following primary tumor removal in mice, Cancer Res, 49, pp. 1996-2001, (1989)

[34] Fisher B, Saffer E, Rudock C, Et al., Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth stimulating factor in mice, Cancer Res, 49, pp. 2002-2004, (1989)

[35] Goldie JH, Coldman AJ, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat Rep, 63, pp. 1727-1733, (1979)

[36] Sorace RA, Bagley CS, Lichter AS, Et al., The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery, World J Surg, 9, pp. 775-785, (1985)

[37] Bonadonna G, Veronesi U, Brambilla C, Et al., Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more, J Natl Cancer Inst, 82, pp. 1539-1545, (1990)

[31] Fisher B, Costantino J, Redmond C, Et al., A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumors, N Engl J Med, 320, pp. 479-484, (1989)

[32] Fisher B, Redmond C, Wickerham L, Et al., Systemic therapy in patients with node‐negative breast cancer: A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials, Ann Intern Med, 111, pp. 703-712, (1989)

[33] Fisher B, Gunduz N, Coyle J, Et al., Presence of a growth‐stimulating factor in serum following primary tumor removal in mice, Cancer Res, 49, pp. 1996-2001, (1989)

[34] Fisher B, Saffer E, Rudock C, Et al., Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth stimulating factor in mice, Cancer Res, 49, pp. 2002-2004, (1989)

[35] Goldie JH, Coldman AJ, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat Rep, 63, pp. 1727-1733, (1979)

[36] Sorace RA, Bagley CS, Lichter AS, Et al., The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery, World J Surg, 9, pp. 775-785, (1985)

[37] Bonadonna G, Veronesi U, Brambilla C, Et al., Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more, J Natl Cancer Inst, 82, pp. 1539-1545, (1990)